All articles tagged with #nasal spray
A nasal spray vaccine, GLA-3M-052-LS+OVA, protected mice against SARS-CoV-2 and other coronaviruses, guarded against certain bacteria, and reduced allergy-related lung symptoms, by engaging both innate and adaptive immunity; with three doses, it lowered lung viral loads and sped up immune responses, and human trials could begin with a target availability in 5–7 years if results translate to people.
A nasal vaccine candidate that trains frontline lung immunity shows promise in mice for broad protection against multiple respiratory infections (cold viruses, flu, and COVID) by boosting alveolar macrophages and T cells rather than targeting a single pathogen; it may also dampen allergic reactions. Human safety and efficacy remain unproven, and the best-case path to a human-ready vaccine is five to seven years, with protection in mice lasting up to about three months and many unknowns, including effects in older adults and on DNA viruses.
Stanford Medicine researchers have developed a nasal spray vaccine that activates the lungs’ innate immune system to provide months-long protection against a broad range of respiratory threats—including SARS-CoV-2, other coronaviruses, bacterial pneumonia pathogens, and even house dust mite allergens—in mice. If safety and efficacy are shown in humans, the approach could reduce the need for multiple yearly vaccines and idea of rapid protection during outbreaks, with Phase I trials moving forward and an estimated 5–7 years before potential availability.
A nationwide recall has been issued for ReBoost Nasal Spray due to contamination with yeast, mold, and microbes, posing health risks especially to immunocompromised individuals. Consumers are advised to stop using the product and return it for a refund, and those experiencing symptoms should consult a healthcare provider. The FDA is collecting reports of reactions, but none have been reported yet.
Research suggests that an over-the-counter nasal spray containing azelastine may reduce the risk of COVID-19 and the common cold, with a phase 2 trial showing fewer infections among users, but more studies are needed before it can be recommended as a preventive measure alongside vaccines and other precautions.
A recent study suggests that nasal sprays, particularly those containing the antihistamine azelastine, may significantly reduce the risk of contracting COVID-19 and the common cold by blocking viruses at the entry point in the nose, though larger studies are needed to confirm these findings.
The upcoming flu season is expected to be severe, prompting health experts to recommend vaccination for everyone six months and older, with new options like the FluMist nasal spray available for self-administration at home, which is especially appealing to children and athletes due to its pain-free application.
A recent trial shows that over-the-counter azelastine nasal spray significantly reduces COVID-19 infection rates by two-thirds, suggesting it could be an effective, affordable, and easy-to-use preventive measure, especially for high-risk groups, though further research is needed before it can be widely recommended.
A recent randomized controlled trial suggests that azelastine nasal spray, an OTC medication, may significantly reduce the risk of COVID-19 infection by 67%, along with other respiratory viruses, though further research is needed to confirm these findings.
A study published in JAMA Internal Medicine found that azelastine, an over-the-counter antihistamine nasal spray, reduced COVID-19 infection risk by 69% in a clinical trial, suggesting potential as a prophylactic measure, especially during respiratory virus seasons.
A small German trial suggests an OTC nasal spray may reduce COVID-19 infections by 67%, offering a potential accessible prophylactic amid limited vaccine access, though further research is needed due to study limitations.
The newly available FluMist Home nasal spray vaccine offers a needle-free, at-home flu vaccination option for children and adults up to age 49, aiming to improve vaccination rates among needle-phobic individuals, with efficacy comparable to traditional flu shots.
FluMist, the FDA-approved nasal spray flu vaccine, is now available for self-administration at home through FluMist Home in 34 states, costing mostly free with insurance and $8.99 for shipping, for individuals aged 2 to 49, with specific safety guidelines and availability restrictions.
AstraZeneca has launched FluMist Home, an at-home delivery service for its nasal spray flu vaccine, approved for self- or caregiver-administration for eligible individuals aged 2-49, aiming to increase vaccination rates and provide a convenient, needle-free option. The vaccine still requires a prescription and is covered by most insurance plans, with shipping costs under $10. It is not suitable for certain populations, including children under 2, pregnant women, and those with specific health conditions.
Researchers have developed a 'molecular shield' using monoclonal antibodies that can intercept mugwort pollen allergens in the nose, showing promising results in mice and potentially offering a new, non-invasive way to prevent allergy symptoms in humans in the future.